#catract

[ruksharmujawar19]

Johnson & Johnson Launches TECNIS PureSee IOL In India For Presbyopia Treatment - BW Healthcare World

Johnson & Johnson has introduced its latest intraocular lens (IOL), TECNIS PureSee, in India, offering patients with presbyopia an advan

Johnson & Johnson Launches TECNIS PureSee IOL In India For Presbyopia Treatment

Johnson & Johnson has introduced its latest intraocular lens (IOL), TECNIS PureSee, in India, offering patients with presbyopia an advanced solution for uninterrupted, high-quality vision. The new IOL features a purely refractive design that delivers superior contrast and low-light performance, similar to a monofocal IOL, enhancing clarity across various distances.

Cataract surgery remains the most commonly performed procedure globally, with approximately 28 million surgeries conducted annually. However, only 10-15 per cent of patients opt for advanced optical IOLs designed to correct astigmatism and presbyopia. Highlighting the significance of the launch, Burzin Shahana, Country Manager, Surgical Vision India & South Asia, Johnson & Johnson MedTech, stated, “We’re proud to launch the TECNIS PureSee IOL, giving surgeons and a growing number of patients in India the choice of a premium IOL that combines clarity of vision and reduced visual symptoms.

[lupine-publishers-tooaj]

Lupine Publishers | Thymoquinone, Lipids and Herbal Medication

Abstract

Allopathic drugs used as hypolipidemic agents have number of unwanted effects. Herbal therapy for Hyperlipidemia is getting attention due to their less frequent side effects. In this study we have compared hypolipidemic effects of Fenofibrate 40 mg with Nigella sativa. Seventy-five hyperlipidemic patients from National Hospital Lahore were enrolled for study. Consent was taken from all enrolled participants and were divided in three equal numbers i.e. twenty-five in each group. Group 1 was on Nigella sativa, group 2 was on Gemfibrozil and third group was on placebo therapy. They were advised to take drugs for two months. After completion of study pretreatment and post treatment values of LDL cholesterol were analyzed statistically. In 25 patients who were on Nigella sativa, their LDL cholesterol decreased from 191.14±3.45 to 159.40±2.98 mg/dl. 31.7 mg/dl LDL reduction was observed when compared with placebo group. In 25 patients who were on Fenofibrate 40 mg, their LDL cholesterol decreased from 197.77±3.91 mg/dl to 159.62±2.20 mg/dl. LDL reduction in this group was 38.2 mg/dl. These changes are highly significant with p-values of <0.001. We concluded from this study that hypolipidemic characteristic of Nigella sativa is comparable and therapeutically as effective as traditionally used hypolipidemic medication Fenofibrate.

Read more about this article https://lupinepublishers.com/ophthalmology-journal/fulltext/thymoquinone-lipids-and-herbal-medication.ID.000145.php

Read more about Lupine Google Scholar: https://scholar.google.com/citations?view_op=view_citation&hl=en&user=T4c9RDkAAAAJ&citation_for_view=T4c9RDkAAAAJ:_Qo2XoVZTnwC

[sriramjanaki]

Best Eye Hospital In Gorakhpur, Diabetic Retinopathy Treatments Hospital In Gorakhpur, Glaucoma Treatment In Gorakhpur, Retina Surgeon In Gorakhpur, Eye Laser Treatment in Gorakhpur, Squint Treatment Doctor in Gorakhpur, Child Eye Problem Doctor In Gorakhpur, Eye Surgeon In Gorakhpur

Best Eye Hospital In Gorakhpur

[dreammeddco]

Catract causes blurry vision left untreated can cause permenant blindness. Free online doctor consultation, find the best online hospitasl and doctors in India, compare hospitals prices list surgery charges and medical treatment in India. Book an appointment

[globaleyelasik]

Everything You Need To Know About Cataract Operation

Are you having difficulty reading or watching television?

Do you experience blurred vision?

Are bright lights make it more challenging to view the surroundings?

https://is.gd/npQpGh

- Global Eye Hospital

[shawnandrew-blog1]

Report: Global Ophthalmic Drugs Market Expected to Reach $42,663 Million by 2023

The global ophthalmic drugs market was valued at $29,613 million in 2016, and is projected to reach $42,663 million by 2023, growing at a

The Global Ophthalmic Drugs Market was valued at $29,613 million in 2016, and is projected to reach $42,663 million by 2023 Rising incidence of glaucoma, cataract, and retinal disorders across the globe Driving Market Growth Key Players@  Actavis Generics (Teva Pharmaceutical Industries Ltd.), Regeneron Pharmaceuticals, Inc., and Pfizer Inc. Read More: https://bit.ly/2ENnkwC